



Heart Failure & Arrhythmias




Pulmonary Hypertension
& Thrombosis



Atherosclerosis
& Ischemic Syndromes



Diabetes & Metabolism



Microcirculation

Focus of research group (I)

Name PI: Marc Vervloet
Department, UMC: Nephrology and ACS
Size of research group: 3 co-PI's, 2 post-docs, 6 PhD candidates

Mission


- Prevent and treat cardiovascular consequences of chronic kidney failure (prevalence 10% in GP....)

Vision

- Unravel mechanisms of disease using translational research in collaborative structures within ACS, other research institutes and consortia also outside Amsterdam UMC and bring this to the clinic (Bedside to bench and back)

Aims


- Study mechanisms of vascular calcification, accelerated atherosclerosis in CKD and uremic cardiomyopathy
- Explore the role of disturbed mineral and endocrine systems in CV complication
- Interrelation between renal osteodystrophy and CV disease




Heart Failure & Arrhythmias




Pulmonary Hypertension
& Thrombosis



Atherosclerosis
& Ischemic Syndromes



Diabetes & Metabolism



Microcirculation


Focus of research group (II)

Current expertise

- Interrelationship between mineral metabolism and arterial medial and endothelial disease
- The role of FGF23, PTH and Klotho on CV complications (Heart & Vessels)
- Animal models of vascular calcification
- Clinical (interventional) research (investigator initiated)
- Large multinational pharma trials

Current funding


- Dutch Kidney Foundation
- Health Holland (Ministry of Economic affairs)
- Horizon2020 (IMPROVE-PD consortium)
- ACS and AMS (Amsterdam Movement Sciences)
- Unrestricted research funding from companies




Heart Failure & Arrhythmias




Pulmonary Hypertension
& Thrombosis



Atherosclerosis
& Ischemic Syndromes



Diabetes & Metabolism



Microcirculation

Future plans

Short term (1-2 year) plan

Plan:

- Explore, mobilize and integrate available expertise within ACS, into research aims as described, from all CoE.
- Intensify collaboration with other research institutes (as now preliminary with AMS and Amsterdam Public Health)

Necessary infrastructure:

- Meetings like this
- Improving visibility within ACS of ongoing research

Long term (>2 year) plan

Plan:

Develop multifactorial approach to combat CV disease in (early) CKD, in subjects with the highest risk for specific complication (personalized)

Necessary infrastructure:

- Support for writing large grants
- Better protection for research time clinicians (not me personally)
- **Much** more cross-talk within and across research institutes

Collaboration in ACS:Current: Other PI's within D&M; Microcirculation (Peter Hordijk), Pieter Koolwijk, Diedrik Kuster, Esther Lutgens (AMC)